mitopodozide has been researched along with Colonic-Neoplasms* in 2 studies
2 other study(ies) available for mitopodozide and Colonic-Neoplasms
Article | Year |
---|---|
Therapy of a xenografted human colonic carcinoma using cisplatin or doxorubicin encapsulated in long-circulating pegylated stealth liposomes.
We compared the therapeutic effects of low doses of cisplatin and doxorubicin hydrochloride encapsulated in long-circulating liposomes composed of cholesterol/hydrogenated soy phosphatidylcholine-polyethylene glycol-distearoyl-phosphatidyl-ethanolamine. The encapsulation of cisplatin and doxorubicin in these liposomes made ineffectively low doses of the free drugs able to inhibit the growth of and affect cures of a human colonic carcinoma growing in nude mice. Liposome-encapsulated cisplatin had minor systemic toxic side effects indicated by an average 9% weight loss which was recovered 3-4 weeks after the last treatment. Toxicity was not observed in mice treated with liposome-encapsulated doxorubicin. Topics: Animals; Antineoplastic Agents; Cisplatin; Colonic Neoplasms; Doxorubicin; Drug Carriers; Female; Humans; Liposomes; Mice; Mice, Nude; Podophyllin; Podophyllotoxin; Polyethylene Glycols; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |
Induction of the transcription factor AP-1 in cultured human colon adenocarcinoma cells following exposure to bile acids.
We studied the effects of bile acids on inducibility of the transcription factor AP-1 in human colon carcinoma LoVo cells. Firstly, cells were treated with chenodeoxycholic acid and the nuclear extracts from those cells were processed by electrophoretic mobility shift assays to analyze nuclear AP-1 DNA-binding activity. We demonstrated that chenodeoxycholic acid induced AP-1 DNA-binding activity in a dose- and time-dependent fashion. Antibody supershift experiments clearly revealed that the majority of protein components in induced AP-1 DNA-binding activity were the products of oncogenes c-fos and c-jun. On the other hand, DNA-binding activity in the nuclear extracts for either NF kappa B, Sp1, or ATF/CREB was not affected by bile acids, suggesting that the effect of bile acids was rather specific for AP-1. Transient transfection experiments supported this notion: expression of the AP-1-luciferase reporter construct was induced by bile acids in a dose-dependent manner, and expression of either reporter construct for NF kappa B, Sp1, or ATF/CREB was not influenced by treatment of the cells with bile acids. We also demonstrated that those bile acids efficiently activated AP-1-dependent promoter in DLD-1 cells, which (as well as LoVo cells), are derived from colon adenocarcinoma, but not in COLO320DM cells which are from colon carcinoid tumor. Thus, we may indicate that bile acids exclusively induce nuclear AP-1 activity in colon adenocarcinoma cells. Topics: Activating Transcription Factor 1; Adenocarcinoma; Base Sequence; Bile Acids and Salts; Chenodeoxycholic Acid; Cholagogues and Choleretics; Cholic Acid; Cholic Acids; Colonic Neoplasms; Deoxycholic Acid; DNA Primers; DNA-Binding Proteins; DNA, Neoplasm; Enzyme Activation; Gene Expression Regulation; Genetic Vectors; Humans; Lithocholic Acid; Molecular Sequence Data; NF-kappa B; Podophyllin; Podophyllotoxin; Protein Kinase C; Tetradecanoylphorbol Acetate; Transcription Factor AP-1; Transcription Factors; Tumor Cells, Cultured; Ursodeoxycholic Acid | 1996 |